30 Presentations Planned On Marketed Products and New Data from Company’s MS Pipeline Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab), will be fea…
Source: New longer-term data on Genzyme’s relapsing MS treatments to be presented at AAN 2015
Wednesday, April 15, 2015
New longer-term data on Genzyme’s relapsing MS treatments to be presented at AAN 2015
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment